David Bond, Md

This study is testing the safety and effectiveness of combining two drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can better contr…

This study is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (called DA-REPOCH) works better for treating aggressive B-cell non-Hodgkin's lymphoma. The goal is to see if this combination helps patients live longer without their cancer g…